This study determined the associations of apolipoprotein A1 (ApoA1), high-density lipoprotein cholesterol (HDL-C), and HDL-C/ApoA1 ratio with fasting blood glucose (FBG) and evaluated the mediating effects of high-sensitivity C-reactive protein (hsCRP) and body mass index (BMI). A cross-sectional study with 4805 coronary artery disease (CAD) patients was performed. In multivariable analyses, higher ApoA1, HDL-C, and HDL-C/ApoA1 ratio were associated with significantly lower FBG level (Q [quartile] 4 vs Q1: 5.67 vs 5.87 mmol/L for ApoA1; 5.64 vs 5.98 mmol/L for HDL-C; 5.63 vs 6.01 mmol/L for HDL-C/ApoA1 ratio). Moreover, inverse associations of ApoA1, HDL-C, and HDL-C/ApoA1 ratio with abnormal FBG (AFBG) were found with odd ratios (95% confidence interval) of .83 (.70–.98), .60 (.50–.71), and .53 (.45–.64) in Q4 compared with Q1. Path analyses indicated that “ApoA1 (or HDL-C)-FBG” associations were mediated by hsCRP and “HDL-C-FBG” association was mediated by BMI. Our data suggested that higher ApoA1, HDL-C, and HDL-C/ApoA1 ratio were favorably associated with a lower FBG level in CAD patients and these associations might be mediated by hsCRP or BMI. Collectively, higher concentrations of ApoA1, HDL-C, and HDL-C/ApoA1 ratio might decrease the risk of AFBG.
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117-171.
2.
The Writing Committee of the Report on Cardiovascular Health and Diseases in ChinaReport on cardiovascular health and diseases in China 2022: an updated summary. Chin Circ J. 2022;38:583-612.
3.
HenningRJ. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol. 2018;14:491-509.
4.
Center for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: U. S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. https://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed May 12, 2017.
5.
FritzenAMDomingo-EspínJLundsgaardAM, et al.ApoA-1 improves glucose tolerance by increasing glucose uptake into heart and skeletal muscle independently of AMPKα(2). Mol Metabol. 2020;35:4.
6.
van der VorstEPC. High-density lipoproteins and apolipoprotein A1. Subcell Biochem. 2020;94:399-420.
7.
CochranBJOngKLManandharBRyeKA. APOA1: a protein with multiple therapeutic functions. Curr Atherosclerosis Rep. 2021;23:11.
8.
SnidermanADMarcovinaSM. Apolipoprotein A1 and B. Clin Lab Med. 2006;26:733-750.
9.
TangSTabetFCochranBJ, et al.Apolipoprotein A-I enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle. Sci Rep. 2019;9:1350.
10.
SiebelALHeywoodSEKingwellBA. HDL and glucose metabolism: current evidence and therapeutic potential. Front Pharmacol. 2015;6:258.
11.
DrewBGDuffySJFormosaMF, et al.High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation. 2009;119:2103-2111.
12.
DuanYWuZLiuB. Relation of plasma glucose levels to serum lipids and apolipoproteins levels in middle and old age males. Hua Xi Yi Ke Da Xue Xue Bao. 2001;32:382-384.
13.
GaoLZhangYWangXDongH. Association of apolipoproteins A1 and B with type 2 diabetes and fasting blood glucose: a cross-sectional study. BMC Endocr Disord. 2021;21:59.
14.
ZhengJGaoYJingY, et al. Gender differences in the relationship between plasma lipids and fasting plasma glucose in non-diabetic urban Chinese population: a cross-section study. Front Med. 2014;8:477-483.
15.
WangSJiXZhangZXueF. Relationship between lipid profiles and glycemic control among patients with type 2 diabetes in Qingdao, China. Int J Environ Res Publ Health. 2020;17:5317.
16.
LiuJHeLQZhuW, et al.Abnormal glucose regulation in Chinese patients with coronary artery disease: a gender analysis. J Cardiothorac Surg. 2022;17:94.
17.
PitsavosCSkoumasIMasouraC, et al.Prevalence and determinants of coronary artery disease in males and females with familial combined hyperlipidaemia. Atherosclerosis. 2008;199:402-407.
18.
HuiNBarterPJOngKLRyeKA. Altered HDL metabolism in metabolic disorders: insights into the therapeutic potential of HDL. Clin Sci2019;133:2221-2235.
19.
CochranBJOngKLManandharBRyeKA. High density lipoproteins and diabetes. Cells. 2021;10:850.
20.
YangSPGongCXCaoBYYanC. Relationship between serum high-sensitivity C-reactive protein and obesity and impaired glycose metabolism in children and adolescents. Zhonghua Er Ke Za Zhi. 2006;44:933-936.
21.
WangYChengYSYinXQYuGJiaBL. Anxa2 gene silencing attenuates obesity-induced insulin resistance by suppressing the NF-κB signaling pathway. Am J Physiol Cell Physiol. 2019;316:C223-C234.
22.
YamadaHUmemotoTKawanoM, et al.High-density lipoprotein and apolipoprotein A-I inhibit palmitate-induced translocation of toll-like receptor 4 into lipid rafts and inflammatory cytokines in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2017;484:403-408.
23.
OoiEMWattsGFFarvidMS, et al.High-density lipoprotein apolipoprotein A-I kinetics in obesity. Obes Res. 2005;13:1008-1016.
24.
MosleyJDGuptaDKTanJ, et al.Predictive accuracy of a polygenic risk score compared with a clinical risk score for incident coronary heart disease. JAMA. 2020;323:627-635.
25.
American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2016;39(Suppl 1):S13-S22.
26.
BaronRMKennyDA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51:1173-1182.
27.
RuanXLiZZhangY, et al.Apolipoprotein A-I possesses an anti-obesity effect associated with increase of energy expenditure and up-regulation of UCP1 in brown fat. J Cell Mol Med. 2011;15:763-772.
28.
LiuBWZhangRJWuZF, et al.Insulin secretion and metabolic changes in maturity onset diabetes mellitus and glucose intolerance. Chin Med J1982;95:829-838.
29.
MellorDDGeorgousopoulouEND’CunhaNM, et al.Association between lipids and apolipoproteins on type 2 diabetes risk; moderating effects of gender and polymorphisms; the ATTICA study. Nutr Metabol Cardiovasc Dis. 2020;30:788-795.
30.
SalomaaVHavulinnaASaarelaO, et al.Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One. 2010;5:0010100.
31.
WuXYuZSuW, et al.Low levels of ApoA1 improve risk prediction of type 2 diabetes mellitus. J Clin Lipidol. 2017;11:362-368.
32.
ChouYCYouSLBaiCHLiaoYCWeiCYSunCA. Utility of apolipoprotein measurements in predicting incident type 2 diabetes: A Chinese cohort study. J Formos Med Assoc. 2020;119:51-58.
33.
MalyalaRRapiLNashMMPrasadGVR. Serum Apolipoprotein B and A1 concentrations predict late-onset posttransplant diabetes mellitus in prevalent adult kidney transplant recipients. Can J Kidney Health Dis. 2019;6:2054358119850536.
34.
HwangYCAhnHYParkSWParkCY. Association of HDL-C and apolipoprotein A-I with the risk of type 2 diabetes in subjects with impaired fasting glucose. Eur J Endocrinol. 2014;171:137-142.
35.
HashemiMSaadatMBehjatiMKelishadiR. Comparison of serum apolipoprotein levels of diabetic children and healthy children with or without diabetic parents. Cholesterol. 2012;2012:1-4.
36.
DrewBGRyeKADuffySJBarterPKingwellBA. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol. 2012;8:237-245.
37.
AbbasiACorpeleijnEGansevoortRT, et al.Role of HDL cholesterol and estimates of HDL particle composition in future development of type 2 diabetes in the general population: the PREVEND study. J Clin Endocrinol Metab. 2013;98:E1352-E1359.
38.
HermansMPAmoussou-GuenouKDBouenizabilaESadikotSSAhnSARousseauMF. Size, density and cholesterol load of HDL predict microangiopathy, coronary artery disease and β-cell function in men with T2DM. Diabetes Metabol Syndr. 2017;11:125-131.
39.
MazerNAGiulianiniFPaynterNPJordanPMoraS. A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study. Clin Chem. 2013;59:949-958.
40.
CochranBJBisoendialRJHouL, et al.Apolipoprotein A-I increases insulin secretion and production from pancreatic β-cells via a G-protein-cAMP-PKA-FoxO1-dependent mechanism. Arterioscler Thromb Vasc Biol. 2014;34:2261-2267.
41.
FryirsMABarterPJAppavooM, et al.Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol. 2010;30:1642-1648.
42.
SuXPengD. The exchangeable apolipoproteins in lipid metabolism and obesity. Clin Chim Acta. 2020;503:128-135.
43.
NavabMReddySTVan LentenBJFogelmanAM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8:222-232.
44.
American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S55-S64.
45.
FragassoGMargonatoASpoladoreRLopaschukGD. Metabolic effects of cardiovascular drugs. Trends Cardiovasc Med. 2019;29:176-187.
46.
MooradianAD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metabol. 2009;5:150-159.
47.
Del Pilar SolanoMGoldbergRB. Management of diabetic dyslipidemia. Endocrinol Metab Clin N Am. 2005;34:1-25.
48.
ChahilTJGinsbergHN. Diabetic dyslipidemia. Endocrinol Metab Clin N Am. 2006;35:491-510.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
